 |
28 Diseases |  |
11 Trials |
|
11 Trials |  |
282 News |  |
| «123456» |
- | entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy: IN-US-0205: Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B (clinicaltrials.gov) - Feb 20, 2018
P4, N=102, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2017 | Trial completion date: Feb 2018 --> Sep 2017 | Initiation date: Sep 2012 --> Sep 2012
- || Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
Trial primary completion date: PAS: PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients (clinicaltrials.gov) - Dec 21, 2017
P4, N=90, Recruiting, Sponsor: Foundation for Liver Research
Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Sep 2017 | Trial completion date: Feb 2018 --> Sep 2017 | Initiation date: Sep 2012 --> Sep 2012 Trial primary completion date: Jun 2018 --> Jun 2019
- | Tyzeka (telbivudine) / Novartis
Trial initiation date, Trial primary completion date: STEN: A Two-year Study of Telbivudine in HBeAg Negative Hepatitis (clinicaltrials.gov) - Oct 24, 2017
P4, N=360, Completed, Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
Trial primary completion date: Jun 2018 --> Jun 2019 Initiation date: Sep 2011 --> Jan 2011 | Trial primary completion date: Feb 2013 --> Feb 2014
- | Vemlidy (tenofovir alafenamide) / Gilead
Enrollment open, Monotherapy: Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. (clinicaltrials.gov) - Oct 24, 2017
P4, N=174, Recruiting, Sponsor: Young-Suk Lim
Initiation date: Sep 2011 --> Jan 2011 | Trial primary completion date: Feb 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- | lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change, Trial initiation date: Prevention of Recurrent Hepatitis B After Liver Transplantation (clinicaltrials.gov) - Oct 18, 2017
P=N/A, N=317, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting --> Recruiting N=500 --> 317 | Initiation date: Jun 2001 --> Mar 2001
- | lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion: Prevention of Recurrent Hepatitis B After Liver Transplantation (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=317, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
N=500 --> 317 | Initiation date: Jun 2001 --> Mar 2001 No longer recruiting --> Completed
- ||||||| tenofovir disoproxil fumarate / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion: Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB) (clinicaltrials.gov) - Sep 19, 2017
P3, N=512, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Pegasys (pegylated interferon ? -2a) / Roche
Enrollment open: The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection (clinicaltrials.gov) - Sep 8, 2017
P4, N=432, Recruiting, Sponsor: Huashan Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Pegasys (pegylated interferon ? -2a) / Roche
New P4 trial: The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection (clinicaltrials.gov) - Aug 17, 2017
P4, N=432, Not yet recruiting, Sponsor: Huashan Hospital
- | Vemlidy (tenofovir alafenamide) / Gilead
New P4 trial, Monotherapy: Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. (clinicaltrials.gov) - Aug 6, 2017
P4, N=174, Not yet recruiting, Sponsor: Young-Suk Lim
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
New P3 trial, Combination therapy, Monotherapy: Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir (clinicaltrials.gov) - Aug 2, 2017
P3, N=76, Active, not recruiting, Sponsor: Uijeongbu St. Mary Hospital
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change, Trial termination: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 28, 2017
P3, N=117, Terminated, Sponsor: National Health Research Institutes, Taiwan
Not yet recruiting --> Recruiting N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment
- | Pegasys (pegylated interferon α -2a) / Roche
New P4 trial: The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC (clinicaltrials.gov) - Mar 20, 2017
P4, N=150, Active, not recruiting, Sponsor: Shanghai Nanhui Nanhua Hospital
- ||||| adefovir dipivoxil / Generic mfg.
New P2 trial: The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Nov 17, 2016
P2, N=180, Recruiting, Sponsor: Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Januvia (sitagliptin) / Merck (MSD), pitavastatin / Generic mfg.
Enrollment closed, Trial primary completion date: Drug Transporter Interaction Study PHENTRA_2015_KPUK (clinicaltrials.gov) - Nov 15, 2016
P4, N=24, Active, not recruiting, Sponsor: University of Cologne
N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2017
- lamivudine HBV / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA (clinicaltrials.gov) - Oct 28, 2016
P4, N=171, Completed, Sponsor: Keimyung University Dongsan Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2017 Active, not recruiting --> Completed
- |||| Pegberon (ypeginterferon alpha-2b) / Xiamen Amoytop Biotech
Trial primary completion date: A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) (clinicaltrials.gov) - Aug 15, 2016
P3, N=300, Recruiting, Sponsor: Tongji Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2018
- || Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
Trial primary completion date: PAS: PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients (clinicaltrials.gov) - Aug 10, 2016
P4, N=90, Recruiting, Sponsor: Foundation for Liver Research
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Oct 2016 --> Jun 2018
- tenofovir disoproxil fumarate / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial primary completion date, Combination therapy: LVL: Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=150, Active, not recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial primary completion date: Oct 2016 --> Jun 2018 Trial primary completion date: Apr 2015 --> Nov 2018
- ||||| Tyzeka (telbivudine) / Novartis
New P4 trial: EFFORT Further Extension Study (clinicaltrials.gov) - Jul 7, 2016
P4, N=130, Active, not recruiting, Sponsor: Nanfang Hospital of Southern Medical University
- Januvia (sitagliptin) / Merck (MSD), pitavastatin / Generic mfg.
New P4 trial: Drug Transporter Interaction Study PHENTRA_2015_KPUK (clinicaltrials.gov) - Apr 19, 2016
P4, N=24, Recruiting, Sponsor: University of Cologne
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial primary completion date: Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients (clinicaltrials.gov) - Apr 1, 2016
P4, N=160, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
Trial primary completion date: Apr 2015 --> Nov 2018 Trial primary completion date: Dec 2016 --> Dec 2019
- || entecavir / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial primary completion date: Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy (clinicaltrials.gov) - Mar 24, 2016
P4, N=255, Recruiting, Sponsor: Seng Gee Lim
Trial primary completion date: Dec 2016 --> Dec 2019 Trial primary completion date: Jan 2016 --> Dec 2017
- ||||||| tenofovir disoproxil fumarate / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion: A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B (clinicaltrials.gov) - Mar 23, 2016
P3, N=266, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Jan 2016 --> Dec 2017 Active, not recruiting --> Completed
- lamivudine HBV / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment closed: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA (clinicaltrials.gov) - Mar 17, 2016
P4, N=171, Active, not recruiting, Sponsor: Keimyung University Dongsan Medical Center
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- ||||||| tenofovir disoproxil fumarate / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Trial initiation date: A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B (clinicaltrials.gov) - Mar 5, 2016
P3, N=375, Completed, Sponsor: Gilead Sciences
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Jun 2005 --> Feb 2005
- || Pegasys (pegylated interferon ? -2a) / Roche
Trial primary completion date: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (clinicaltrials.gov) - Dec 4, 2015
P4, N=255, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | Initiation date: Jun 2005 --> Feb 2005 Trial primary completion date: Sep 2008 --> Apr 2009
- ||||| Pegasys (pegylated interferon ? -2a) / Roche
New P4 trial: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (clinicaltrials.gov) - Nov 6, 2015
P4, N=255, Completed, Sponsor: Hoffmann-La Roche
- | Pegasys (pegylated interferon α -2a) / Roche
New P4 trial: An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients (clinicaltrials.gov) - Sep 25, 2015
P4, N=324, Active, not recruiting, Sponsor: Ruijin Hospital
- entecavir / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change: Entecavir Plus Adefovir in Lamivudine-Resistant Patients (clinicaltrials.gov) - Sep 2, 2015
P4, N=0, Withdrawn, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2008 --> Apr 2009 N=420 --> 0
- lamivudine HBV / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, HEOR, Cost effectiveness: Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=621, Active, not recruiting, Sponsor: Beijing Friendship Hospital
N=420 --> 0 Recruiting --> Active, not recruiting | N=800 --> 621 | Trial primary completion date: Dec 2014 --> Dec 2015
- | entecavir / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
New P4 trial, Monotherapy: Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B (clinicaltrials.gov) - Jun 26, 2015
P4, N=90, Recruiting, Sponsor: Asan Medical Center
- Tyzeka (telbivudine) / Novartis
Trial completion: Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B (clinicaltrials.gov) - May 10, 2015
P3, N=0, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting | N=800 --> 621 | Trial primary completion date: Dec 2014 --> Dec 2015 No longer recruiting --> Completed
- || Pegasys (pegylated interferon ? -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
Trial primary completion date: PAS: PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients (clinicaltrials.gov) - Mar 14, 2015
P4, N=90, Recruiting, Sponsor: Foundation for Liver Research
No longer recruiting --> Completed Trial primary completion date: Oct 2014 --> Oct 2016
- |||||||||| Zadaxin (thymalfasin) / SciClone
New P3 trial: Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B (clinicaltrials.gov) - Feb 19, 2015
P3, N=463, Active, not recruiting, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- ||||| Zadaxin (thymalfasin) / SciClone
New P2 trial: Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B (clinicaltrials.gov) - Feb 19, 2015
P2, N=116, Completed, Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
- tenofovir disoproxil fumarate / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy: LVL: Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial primary completion date: Oct 2014 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Apr 2015
- | emtricitabine / Generic mfg., adefovir dipivoxil / Generic mfg.
New P4 trial: Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients (clinicaltrials.gov) - Dec 30, 2014
P4, N=400, Not yet recruiting, Sponsor: Asian-Pacific Alliance of Liver Disease, Beijing
- |||||||||| Pegberon (ypeginterferon alpha-2b) / Xiamen Amoytop Biotech
New P3 trial: A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) (clinicaltrials.gov) - Dec 30, 2014
P3, N=300, Recruiting, Sponsor: Tongji Hospital
- | Levovir (clevudine) / Bukwang Pharma, Eisai
Trial termination, Monotherapy: A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Dec 19, 2014
P4, N=200, Terminated, Sponsor: Bukwang Pharmaceutical
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Apr 2015 Active, not recruiting --> Terminated
- |||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion, Monotherapy: An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B (clinicaltrials.gov) - Dec 19, 2014
P4, N=60, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Terminated Active, not recruiting --> Completed
- ||||||| Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion: A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B (clinicaltrials.gov) - Dec 19, 2014
P3, N=102, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Levovir (clevudine) / Bukwang Pharma, Eisai
Trial completion, Trial primary completion date, Monotherapy: A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC (clinicaltrials.gov) - Dec 19, 2014
P4, N=33, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jan 2013
- entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Trial primary completion date: Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=242, Completed, Sponsor: Ying-Jie Ji
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jan 2013 Enrolling by invitation --> Completed | Trial primary completion date: Dec 2014 --> Oct 2012
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion, Trial primary completion date: Lamivudine and Adefovir to Treat Chronic Hepatitis B (clinicaltrials.gov) - Jul 27, 2014
P2, N=41, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2014 --> Oct 2012 Active, not recruiting --> Completed | Trial primary completion date: Jul 2010 --> Apr 2010
- entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment open: Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=300, Enrolling by invitation, Sponsor: Ying-Jie Ji
Active, not recruiting --> Completed | Trial primary completion date: Jul 2010 --> Apr 2010 Active, not recruiting --> Enrolling by invitation
- entecavir / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment closed: 3E Extension Study (clinicaltrials.gov) - Jun 19, 2014
P4, N=600, Active, not recruiting, Sponsor: Nanfang Hospital of Southern Medical University
Active, not recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- entecavir / Generic mfg.
Enrollment closed: Dragon-Ex: Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy (clinicaltrials.gov) - Jun 19, 2014
P4, N=360, Active, not recruiting, Sponsor: Nanfang Hospital of Southern Medical University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion date: Lamivudine and Adefovir to Treat Chronic Hepatitis B (clinicaltrials.gov) - Apr 24, 2014
P2, N=41, Active, not recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Active, not recruiting Trial completion date: Sep 2013 --> Sep 2017
- ||| Pegasys (pegylated interferon α -2a) / Roche
Trial initiation date, Combination therapy: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B (clinicaltrials.gov) - Mar 30, 2014
P4, N=281, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2013 --> Sep 2017 Initiation date: Aug 2008 --> May 2010